首页 > 最新文献

BMC Clinical Pathology最新文献

英文 中文
High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival. EphA3(促红细胞生成素生成肝细胞A3)在胃癌中的高表达与转移和低生存率相关。
Q2 Medicine Pub Date : 2017-04-27 eCollection Date: 2017-01-01 DOI: 10.1186/s12907-017-0047-y
Baongoc Nasri, Mikito Inokuchi, Toshiaki Ishikawa, Hiroyuki Uetake, Yoko Takagi, Sho Otsuki, Kazuyuki Kojima, Tatsuyuki Kawano

Background: As the major subfamily of receptor tyrosine, erythropoietin-producing hepatocellular (Eph) receptor has been related to progression and prognosis in different types of tumors. However, the role and mechanism of EPHA3 in gastric cancer is still not well understood.

Methods: Specimen were collected from 202 patients who underwent gastric resection for gastric adenocarcinoma. The expression of EphA3 was studied using immunohistochemistry. We analyzed the clinicopathological factors and prognostic relevance of EphA3 expression in gastric cancer.

Results: High expression of EphA3 was associated with male predominance (p = 0.031), differentiated histology (p < 0.001), depth of tumor (p = 0.002), lymph node metastasis (p = 0.001), distant metastasis (p = 0.021), liver metastasis (p = 0.024), advanced stage (p < 0.001), and high HER2 expression (p = 0.017). Relapse-free survival (RFS) was significantly worse in patients with high expression of EphA3 than in those with low expression of EphA3 (p = 0.014). Multivariate analysis for RFS showed that depth of tumor [hazard ratio (HR) 9.333, 95% confidence interval (CI) 2.183-39.911, p = 0.003] and lymph node metastasis [hazard ratio (HR) 5.734, 95% confidence interval (CI) 2.349-13.997, p < 0.001] were independent prognostic factors.

Conclusions: These findings suggest that high expression EphA3 may participate in metastasis and worse survival.

背景:促红细胞生成素产生肝细胞(Eph)受体作为酪氨酸受体的主要亚家族,与不同类型肿瘤的进展和预后有关。然而,EPHA3在胃癌中的作用和机制尚不清楚。方法:收集202例胃腺癌切除术患者标本。免疫组化法检测EphA3的表达。我们分析胃癌中EphA3表达的临床病理因素及与预后的相关性。结果:EphA3高表达与男性优势(p = 0.031)、分化组织学(p = 0.002)、淋巴结转移(p = 0.001)、远处转移(p = 0.021)、肝转移(p = 0.024)、晚期(p = 0.017)相关。EphA3高表达患者的无复发生存期(RFS)明显低于EphA3低表达患者(p = 0.014)。RFS多因素分析显示肿瘤深度[危险比(HR) 9.333, 95%可信区间(CI) 2.183 ~ 39.911, p = 0.003]和淋巴结转移[危险比(HR) 5.734, 95%可信区间(CI) 2.349 ~ 13.997, p]。结论:高表达EphA3可能参与了肿瘤转移,生存率较差。
{"title":"High expression of EphA3 (erythropoietin-producing hepatocellular A3) in gastric cancer is associated with metastasis and poor survival.","authors":"Baongoc Nasri,&nbsp;Mikito Inokuchi,&nbsp;Toshiaki Ishikawa,&nbsp;Hiroyuki Uetake,&nbsp;Yoko Takagi,&nbsp;Sho Otsuki,&nbsp;Kazuyuki Kojima,&nbsp;Tatsuyuki Kawano","doi":"10.1186/s12907-017-0047-y","DOIUrl":"https://doi.org/10.1186/s12907-017-0047-y","url":null,"abstract":"<p><strong>Background: </strong>As the major subfamily of receptor tyrosine, erythropoietin-producing hepatocellular (Eph) receptor has been related to progression and prognosis in different types of tumors. However, the role and mechanism of EPHA3 in gastric cancer is still not well understood.</p><p><strong>Methods: </strong>Specimen were collected from 202 patients who underwent gastric resection for gastric adenocarcinoma. The expression of EphA3 was studied using immunohistochemistry. We analyzed the clinicopathological factors and prognostic relevance of EphA3 expression in gastric cancer.</p><p><strong>Results: </strong>High expression of EphA3 was associated with male predominance (<i>p</i> = 0.031), differentiated histology (<i>p</i> < 0.001), depth of tumor (<i>p</i> = 0.002), lymph node metastasis (<i>p</i> = 0.001), distant metastasis (<i>p</i> = 0.021), liver metastasis (<i>p</i> = 0.024), advanced stage (<i>p</i> < 0.001), and high HER2 expression (<i>p</i> = 0.017). Relapse-free survival (RFS) was significantly worse in patients with high expression of EphA3 than in those with low expression of EphA3 (<i>p</i> = 0.014). Multivariate analysis for RFS showed that depth of tumor [hazard ratio (HR) 9.333, 95% confidence interval (CI) 2.183-39.911, <i>p</i> = 0.003] and lymph node metastasis [hazard ratio (HR) 5.734, 95% confidence interval (CI) 2.349-13.997, <i>p</i> < 0.001] were independent prognostic factors.</p><p><strong>Conclusions: </strong>These findings suggest that high expression EphA3 may participate in metastasis and worse survival.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"17 ","pages":"8"},"PeriodicalIF":0.0,"publicationDate":"2017-04-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0047-y","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34961473","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 20
Mapping mitochondrial heteroplasmy in a Leydig tumor by laser capture micro-dissection and cycling temperature capillary electrophoresis. 激光捕获显微解剖和循环温度毛细管电泳在间质瘤中定位线粒体异质性。
Q2 Medicine Pub Date : 2017-04-08 eCollection Date: 2017-01-01 DOI: 10.1186/s12907-017-0042-3
Paulo Refinetti, Christian Arstad, William G Thilly, Stephan Morgenthaler, Per Olaf Ekstrøm

Background: The growth of tumor cells is accompanied by mutations in nuclear and mitochondrial genomes creating marked genetic heterogeneity. Tumors also contain non-tumor cells of various origins. An observed somatic mitochondrial mutation would have occurred in a founding cell and spread through cell division. Micro-anatomical dissection of a tumor coupled with assays for mitochondrial point mutations permits new insights into this growth process. More generally, the ability to detect and trace, at a histological level, somatic mitochondrial mutations in human tissues and tumors, makes these mutations into markers for lineage tracing.

Method: A tumor was first sampled by a large punch biopsy and scanned for any significant degree of heteroplasmy in a set of sequences containing known mutational hotspots of the mitochondrial genome. A heteroplasmic tumor was sliced at a 12 μm thickness and placed on membranes. Laser capture micro-dissection was used to take 25000 μm2 subsamples or spots. After DNA amplification, cycling temperature capillary electrophoresis (CTCE) was used on the laser captured samples to quantify mitochondrial mutant fractions.

Results: Of six testicular tumors studied, one, a Leydig tumor, was discovered to carry a detectable degree of heteroplasmy for two separate point mutations: a C → T mutation at bp 64 and a T → C mutation found at bp 152. From this tumor, 381 spots were sampled with laser capture micro-dissection. The ordered distribution of spots exhibited a wide range of fractions of the mutant sequences from 0 to 100% mutant copies. The two mutations co-distributed in the growing tumor indicating they were present on the same genome copies in the founding cell.

Conclusion: Laser capture microdissection of sliced tumor samples coupled with CTCE-based point mutation assays provides an effective and practical means to obtain maps of mitochondrial mutational heteroplasmy within human tumors.

背景:肿瘤细胞的生长伴随着细胞核和线粒体基因组的突变,产生显著的遗传异质性。肿瘤也包含各种来源的非肿瘤细胞。观察到的体细胞线粒体突变可能发生在创始细胞中,并通过细胞分裂传播。肿瘤的显微解剖加上线粒体点突变的测定允许对这一生长过程的新见解。更一般地说,在组织学水平上检测和追踪人体组织和肿瘤中的体细胞线粒体突变的能力,使这些突变成为谱系追踪的标记。方法:首先通过大穿孔活检对肿瘤进行取样,并在一组包含已知线粒体基因组突变热点的序列中扫描任何显著程度的异质性。将异质瘤切成12 μm厚,置于膜上。采用激光捕获显微解剖法,取25000 μm2的亚样或斑点。DNA扩增后,对激光捕获的样品进行循环温度毛细管电泳(CTCE),定量线粒体突变体组分。结果:在研究的6个睾丸肿瘤中,发现一个Leydig肿瘤携带两个不同点突变的可检测程度的异质性:在bp 64处发现C→T突变,在bp 152处发现T→C突变。从该肿瘤中,用激光捕获显微解剖取样381个斑点。斑点的有序分布显示了突变序列从0到100%突变拷贝的广泛范围。这两种突变在生长中的肿瘤中共同分布,表明它们存在于创始细胞的相同基因组拷贝上。结论:激光捕获显微解剖切片肿瘤样品,结合基于ctce的点突变检测,为获得人类肿瘤内线粒体突变异质性图谱提供了一种有效而实用的手段。
{"title":"Mapping mitochondrial heteroplasmy in a Leydig tumor by laser capture micro-dissection and cycling temperature capillary electrophoresis.","authors":"Paulo Refinetti,&nbsp;Christian Arstad,&nbsp;William G Thilly,&nbsp;Stephan Morgenthaler,&nbsp;Per Olaf Ekstrøm","doi":"10.1186/s12907-017-0042-3","DOIUrl":"https://doi.org/10.1186/s12907-017-0042-3","url":null,"abstract":"<p><strong>Background: </strong>The growth of tumor cells is accompanied by mutations in nuclear and mitochondrial genomes creating marked genetic heterogeneity. Tumors also contain non-tumor cells of various origins. An observed somatic mitochondrial mutation would have occurred in a founding cell and spread through cell division. Micro-anatomical dissection of a tumor coupled with assays for mitochondrial point mutations permits new insights into this growth process. More generally, the ability to detect and trace, at a histological level, somatic mitochondrial mutations in human tissues and tumors, makes these mutations into markers for lineage tracing.</p><p><strong>Method: </strong>A tumor was first sampled by a large punch biopsy and scanned for any significant degree of heteroplasmy in a set of sequences containing known mutational hotspots of the mitochondrial genome. A heteroplasmic tumor was sliced at a 12 μm thickness and placed on membranes. Laser capture micro-dissection was used to take 25000 μm<sup>2</sup> subsamples or spots. After DNA amplification, cycling temperature capillary electrophoresis (CTCE) was used on the laser captured samples to quantify mitochondrial mutant fractions.</p><p><strong>Results: </strong>Of six testicular tumors studied, one, a Leydig tumor, was discovered to carry a detectable degree of heteroplasmy for two separate point mutations: a C → T mutation at bp 64 and a T → C mutation found at bp 152. From this tumor, 381 spots were sampled with laser capture micro-dissection. The ordered distribution of spots exhibited a wide range of fractions of the mutant sequences from 0 to 100% mutant copies. The two mutations co-distributed in the growing tumor indicating they were present on the same genome copies in the founding cell.</p><p><strong>Conclusion: </strong>Laser capture microdissection of sliced tumor samples coupled with CTCE-based point mutation assays provides an effective and practical means to obtain maps of mitochondrial mutational heteroplasmy within human tumors.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"17 ","pages":"6"},"PeriodicalIF":0.0,"publicationDate":"2017-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0042-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34909948","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Utilizing BD MAX™ Enteric Bacterial Panel to Detect Stool Pathogens from Rectal Swabs. 利用BD MAX™肠道细菌检测板检测直肠拭子中的粪便病原体。
Q2 Medicine Pub Date : 2017-04-08 eCollection Date: 2017-01-01 DOI: 10.1186/s12907-017-0043-2
Barbara DeBurger, Sarah Hanna, Eleanor A Powell, Cindi Ventrola, Joel E Mortensen

Background: The BD MAX™ Enteric Bacterial Panel (BDM-EBP) is designed and FDA-cleared to detect Salmonella, Shigella, Campylobacter, and Shiga toxin genes stx1/2 from stool samples. However, rectal swabs, which are not FDA-cleared for clinical testing with the BDM-EBP, are common specimens received from pediatric patients for enteric pathogen testing. The purpose of this study was to evaluate the ability of the BDM-EBP to detect stool pathogens from rectal swabs.

Methods: Routine cultures, Shiga toxin testing, and molecular testing with BDM-EBP were performed on 272 sequential rectal swabs collected from August 2015 to December 2015. Discrepant test results were resolved using Verigene® Enteric Pathogens Nucleic Acid Test (EP). 36 challenge samples (13 Salmonella spp., 3 Shigella spp., 10 Campylobacter spp., and 10 Shiga toxin positive Escherichia coli) were tested using reference strains (American Type Culture Collection) and previous patient isolates diluted to103-104 cfu/ml in saline then added to Sample Buffer Tube (SBT) with negative stool matrix delivered via a swab. Limit of detection testing was performed by serial 10 fold dilutions in saline then added to SBT with negative stool matrix provided via a swab.

Results: A total of 272 rectal swab specimens were evaluated and 89 were positive by culture and/or MAX EBP. All discrepant results were BDM-EBP positive and culture negative. 21 of 31 (68%) of the apparent false positive BDM-EBP discrepant results resolved as positive with Nanosphere's Verigene® EP. After resolution of the discordant results, the Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) are as follows for each target: Salmonella (n = 4) 100%, PPA and 100%, NPA; Shigella (n = 79) 100%, PPA and 95.3%, NPA; Campylobacter (n = 4) 100%, PPA and 99.6%, NPA; and Shiga toxin producing organisms (n = 2) 100%, PPA and 100%, NPA. 8.8% of the patient samples did not initially yield a result on the BDM-System. Upon repeat, half of the problematic samples resolved, and 4.4% of the total specimen tested did not yield a result. All organisms in the challenge samples were detected. Limits of detection for BDM-EBP testing of rectal swabs were as follows (in cfu/ml in SBT): Salmonella-1.44 × 102; Shigella-5.10 × 100; Campylobacter-1.51 × 101; and Shiga Toxin-1.13 ×103.

Conclusion: Rectal swabs are acceptable samples for detecting Salmonella, Shigella, Campylobacter, and Shiga toxin using BDM-EBP.

背景:BDM-EBP是专为检测粪便样本中的沙门氏菌、志贺氏菌、弯曲杆菌和志贺氏毒素基因stx1/2而设计并获得fda批准的。然而,直肠拭子,不被fda批准用于BDM-EBP的临床测试,是儿科患者用于肠道病原体测试的常见标本。本研究的目的是评估BDM-EBP检测直肠拭子粪便病原体的能力。方法:对2015年8月~ 2015年12月收集的272份直肠拭子进行常规培养、志贺毒素检测和BDM-EBP分子检测。使用Verigene®肠道病原体核酸检测(EP)解决检测结果的差异。36份攻毒样本(13份沙门氏菌、3份志贺氏菌、10份弯曲杆菌和10份志贺氏毒素阳性的大肠杆菌)使用参考菌株(美国型培养收集)进行检测,之前的患者分离株在生理盐水中稀释至103-104 cfu/ml,然后加入样本缓冲管(SBT),阴性粪便基质通过拭子输送。检测极限试验是通过连续将生理盐水稀释10倍,然后加入SBT,通过拭子提供阴性粪便基质。结果:共对272例直肠拭子标本进行了评估,其中89例经培养和/或MAX EBP检测呈阳性。所有差异结果均为BDM-EBP阳性,培养阴性。31例明显假阳性BDM-EBP差异结果中有21例(68%)用Nanosphere的Verigene®EP解决为阳性。在解决不一致的结果后,每个目标的阳性百分比协议(PPA)和阴性百分比协议(NPA)如下:沙门氏菌(n = 4) 100%, PPA和100%,NPA;志贺氏菌(n = 79) 100%为PPA, 95.3%为NPA;弯曲杆菌(n = 4) 100%为PPA, 99.6%为NPA;和志贺毒素产生生物(n = 2) 100%, PPA和100%,NPA。8.8%的患者样本最初在bdm系统上没有产生结果。重复后,半数有问题的样品得到解决,4.4%的总样品测试没有产生结果。攻毒样品中的所有生物均被检测到。直肠拭子BDM-EBP检测的检出限如下(SBT中以cfu/ml计):沙门氏菌-1.44 × 102;志贺氏菌-5.10 × 100;弯曲杆菌-1.51 × 101;志贺毒素-1.13 ×103。结论:用BDM-EBP检测直肠拭子可用于沙门氏菌、志贺氏菌、弯曲杆菌和志贺氏毒素。
{"title":"Utilizing BD MAX™ Enteric Bacterial Panel to Detect Stool Pathogens from Rectal Swabs.","authors":"Barbara DeBurger,&nbsp;Sarah Hanna,&nbsp;Eleanor A Powell,&nbsp;Cindi Ventrola,&nbsp;Joel E Mortensen","doi":"10.1186/s12907-017-0043-2","DOIUrl":"https://doi.org/10.1186/s12907-017-0043-2","url":null,"abstract":"<p><strong>Background: </strong>The BD MAX™ Enteric Bacterial Panel (BDM-EBP) is designed and FDA-cleared to detect <i>Salmonella, Shigella, Campylobacter,</i> and Shiga toxin genes <i>stx1/2</i> from stool samples. However, rectal swabs, which are not FDA-cleared for clinical testing with the BDM-EBP, are common specimens received from pediatric patients for enteric pathogen testing. The purpose of this study was to evaluate the ability of the BDM-EBP to detect stool pathogens from rectal swabs.</p><p><strong>Methods: </strong>Routine cultures, Shiga toxin testing, and molecular testing with BDM-EBP were performed on 272 sequential rectal swabs collected from August 2015 to December 2015. Discrepant test results were resolved using Verigene® Enteric Pathogens Nucleic Acid Test (EP). 36 challenge samples (13 <i>Salmonella</i> spp., 3 <i>Shigella</i> spp., 10 <i>Campylobacter</i> spp., and 10 Shiga toxin positive <i>Escherichia coli</i>) were tested using reference strains (American Type Culture Collection) and previous patient isolates diluted to10<sup>3</sup>-10<sup>4</sup> cfu/ml in saline then added to Sample Buffer Tube (SBT) with negative stool matrix delivered via a swab. Limit of detection testing was performed by serial 10 fold dilutions in saline then added to SBT with negative stool matrix provided via a swab.</p><p><strong>Results: </strong>A total of 272 rectal swab specimens were evaluated and 89 were positive by culture and/or MAX EBP. All discrepant results were BDM-EBP positive and culture negative. 21 of 31 (68%) of the apparent false positive BDM-EBP discrepant results resolved as positive with Nanosphere's Verigene® EP. After resolution of the discordant results, the Positive Percent Agreement (PPA) and Negative Percent Agreement (NPA) are as follows for each target: <i>Salmonella</i> (<i>n</i> = 4) 100%, PPA and 100%, NPA; <i>Shigella</i> (<i>n</i> = 79) 100%, PPA and 95.3%, NPA; <i>Campylobacter</i> (<i>n</i> = 4) 100%, PPA and 99.6%, NPA; and Shiga toxin producing organisms (<i>n</i> = 2) 100%, PPA and 100%, NPA. 8.8% of the patient samples did not initially yield a result on the BDM-System. Upon repeat, half of the problematic samples resolved, and 4.4% of the total specimen tested did not yield a result. All organisms in the challenge samples were detected. Limits of detection for BDM-EBP testing of rectal swabs were as follows (in cfu/ml in SBT): <i>Salmonella</i>-1.44 × 10<sup>2</sup>; <i>Shigella</i>-5.10 × 10<sup>0</sup>; <i>Campylobacter</i>-1.51 × 10<sup>1</sup>; and Shiga Toxin-1.13 ×10<sup>3</sup>.</p><p><strong>Conclusion: </strong>Rectal swabs are acceptable samples for detecting <i>Salmonella</i>, <i>Shigella</i>, <i>Campylobacter</i>, and Shiga toxin using BDM-EBP.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"17 ","pages":"7"},"PeriodicalIF":0.0,"publicationDate":"2017-04-08","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0043-2","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34909820","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 16
Bone pathologic fracture revealing an unusual association: coexistence of Langerhans cell histiocytosis with Rosai-Dorfman disease. 骨病理性骨折揭示了一种不寻常的关联:朗格汉斯细胞组织细胞增多症与罗赛-多尔夫曼病共存。
Q2 Medicine Pub Date : 2017-04-07 eCollection Date: 2017-01-01 DOI: 10.1186/s12907-017-0044-1
Boubacar Efared, Asmae Mazti, Badarou Chaibou, Gabrielle Atsame-Ebang, Ibrahim Sory Sidibé, Layla Tahiri, Fatimazahra Erregad, Nawal Hammas, Abdelmajid El Mrini, Hinde El Fatemi, Laila Chbani

Background: The coexistence of Rosai-Dorfman disease (RDD) with Langerhans cell histiocytosis (LCH) is very rare, as to date only 17 cases have been reported in the english literature. The pathophysiology of this uncommon co-occurrence still remains enigmatic and a subject of various speculations.

Case presentation: We report a case of a 30-year-old female patient who presented with a pathologic fracture of the left proximal femur. Her medical history was unremarkable, there were no fever, skin lesions, lymphadenopathy or other organomegaly at physical examination. X-ray radiograph of the fractured femur showed an isolated and ill-defined osteolytic lesion. The histopathological analysis of biopsies from this lesion were consistent with a combined RDD-LCH of the bone.

Conclusion: Combined RDD-LCH is a very rare phenomenon, whose pathophysiology still remains unclear and a subject of various speculations.

背景:rossai - dorfman病(RDD)与朗格汉斯细胞组织细胞增多症(LCH)共存是非常罕见的,迄今为止在英文文献中仅报道了17例。这种罕见的共发生的病理生理学仍然是一个谜,也是各种猜测的主题。病例介绍:我们报告一例30岁的女性患者谁提出了病理性骨折的左股骨近端。病史无明显变化,体格检查无发热、皮肤病变、淋巴结病变及其他器官肿大。股骨骨折的x线片显示一个孤立的和不明确的溶骨性病变。该病变活检的组织病理学分析与骨的RDD-LCH联合一致。结论:联合RDD-LCH是一种非常罕见的现象,其病理生理机制尚不清楚,存在多种推测。
{"title":"Bone pathologic fracture revealing an unusual association: coexistence of Langerhans cell histiocytosis with Rosai-Dorfman disease.","authors":"Boubacar Efared,&nbsp;Asmae Mazti,&nbsp;Badarou Chaibou,&nbsp;Gabrielle Atsame-Ebang,&nbsp;Ibrahim Sory Sidibé,&nbsp;Layla Tahiri,&nbsp;Fatimazahra Erregad,&nbsp;Nawal Hammas,&nbsp;Abdelmajid El Mrini,&nbsp;Hinde El Fatemi,&nbsp;Laila Chbani","doi":"10.1186/s12907-017-0044-1","DOIUrl":"https://doi.org/10.1186/s12907-017-0044-1","url":null,"abstract":"<p><strong>Background: </strong>The coexistence of Rosai-Dorfman disease (RDD) with Langerhans cell histiocytosis (LCH) is very rare, as to date only 17 cases have been reported in the english literature. The pathophysiology of this uncommon co-occurrence still remains enigmatic and a subject of various speculations.</p><p><strong>Case presentation: </strong>We report a case of a 30-year-old female patient who presented with a pathologic fracture of the left proximal femur. Her medical history was unremarkable, there were no fever, skin lesions, lymphadenopathy or other organomegaly at physical examination. X-ray radiograph of the fractured femur showed an isolated and ill-defined osteolytic lesion. The histopathological analysis of biopsies from this lesion were consistent with a combined RDD-LCH of the bone.</p><p><strong>Conclusion: </strong>Combined RDD-LCH is a very rare phenomenon, whose pathophysiology still remains unclear and a subject of various speculations.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"17 ","pages":"5"},"PeriodicalIF":0.0,"publicationDate":"2017-04-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0044-1","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34901434","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 8
Can takotsubo cardiomyopathy be diagnosed by autopsy? Report of a presumed case presenting as cardiac rupture. takotsubo型心肌病可以通过尸检诊断吗?报告一个疑似心脏破裂的病例。
Q2 Medicine Pub Date : 2017-04-05 eCollection Date: 2017-01-01 DOI: 10.1186/s12907-017-0045-0
Andrew Mitchell, François Marquis

Background: Takostsubo (stress) cardiomyopathy (TC) is a clinical syndrome featuring transient left ventricular dysfunction and wall-motion abnormalities, usually following emotional or physical stress. The diagnosis of TC depends on fulfillment of multiple clinical criteria. Although the pathogenesis has not been firmly established, myocardial cathecholamine toxicity is thought to represent a primary mechanism. The vast majority of patients with TC survive. However, a rare cause of death in TC is myocardial rupture. All documented cases of rupture have followed known, recently diagnosed or suspected TC. However, in this report we propose that an initial diagnosis of TC with myocardial rupture can be made by autopsy when supported by a compelling clinical history and appropriate histologic changes in the myocardium.

Case presentation: An 82 year-old female underwent elective craniotomy for a recently discovered craniopharyngioma. The surgery was uneventful; the initial postoperative course featured diabetes insipidus and delirium. With no prior warning, on the third postoperative day she was found unresponsive in bed. Two prolonged cardiopulmonary resuscitations were successful, however, during a third arrest maneuvers were stopped at the request of the family. An autopsy was conducted which revealed hemopericardium due to cardiac rupture. Coronary artery atherosclerosis, valve disease, and renal and extra-renal pheochromocytoma were absent. Microscopy of the myocardium showed a recent, localized, transmural myocardial infarction and diffuse changes (all four ventricles) typical of cathecholamine cardiomyopathy. The findings were considered compatible with TC with secondary myocardial rupture.

Conclusion: An initial diagnosis of TC with myocardial rupture can be reasonably made by autopsy in the context of an appropriate clinical history and the presence of the characteristic microscopic features of cathecholamine excess in the myocardium.

背景:应激性心肌病(Takostsubo cardiomyopathy, TC)是一种以短暂性左心室功能障碍和壁面运动异常为特征的临床综合征,通常由情绪或身体压力引起。TC的诊断需要满足多种临床标准。虽然发病机制尚未明确,但心肌儿茶酚胺毒性被认为是主要机制。绝大多数TC患者存活。然而,心肌破裂是罕见的TC死亡原因。所有记录的破裂病例都是在已知的、最近诊断的或疑似TC之后发生的。然而,在本报告中,我们建议,当有令人信服的临床病史和适当的心肌组织学改变支持时,可以通过尸检来初步诊断心肌破裂的TC。病例介绍:一名82岁女性因最近发现颅咽管瘤而行择期开颅手术。手术很顺利;术后初期病程以尿崩症及谵妄为特征。在没有事先警告的情况下,术后第三天发现她在床上没有反应。两次延长心肺复苏术是成功的,然而,在第三次逮捕演习中,应家属的要求停止了。尸检结果显示心脏破裂导致心包积血。无冠状动脉粥样硬化、瓣膜疾病、肾及肾外嗜铬细胞瘤。心肌镜检显示最近发生的局部、跨壁心肌梗死和弥漫性改变(所有四个心室),是典型的儿茶酚胺性心肌病。这些结果被认为与继发性心肌破裂的TC一致。结论:对TC合并心肌破裂的初步诊断可以在适当的临床病史和心肌中儿茶酚胺过量的特征性显微镜特征的背景下通过尸检做出合理的诊断。
{"title":"Can takotsubo cardiomyopathy be diagnosed by autopsy? Report of a presumed case presenting as cardiac rupture.","authors":"Andrew Mitchell,&nbsp;François Marquis","doi":"10.1186/s12907-017-0045-0","DOIUrl":"https://doi.org/10.1186/s12907-017-0045-0","url":null,"abstract":"<p><strong>Background: </strong>Takostsubo (stress) cardiomyopathy (TC) is a clinical syndrome featuring transient left ventricular dysfunction and wall-motion abnormalities, usually following emotional or physical stress. The diagnosis of TC depends on fulfillment of multiple clinical criteria. Although the pathogenesis has not been firmly established, myocardial cathecholamine toxicity is thought to represent a primary mechanism. The vast majority of patients with TC survive. However, a rare cause of death in TC is myocardial rupture. All documented cases of rupture have followed known, recently diagnosed or suspected TC. However, in this report we propose that an initial diagnosis of TC with myocardial rupture can be made by autopsy when supported by a compelling clinical history and appropriate histologic changes in the myocardium.</p><p><strong>Case presentation: </strong>An 82 year-old female underwent elective craniotomy for a recently discovered craniopharyngioma. The surgery was uneventful; the initial postoperative course featured diabetes insipidus and delirium. With no prior warning, on the third postoperative day she was found unresponsive in bed. Two prolonged cardiopulmonary resuscitations were successful, however, during a third arrest maneuvers were stopped at the request of the family. An autopsy was conducted which revealed hemopericardium due to cardiac rupture. Coronary artery atherosclerosis, valve disease, and renal and extra-renal pheochromocytoma were absent. Microscopy of the myocardium showed a recent, localized, transmural myocardial infarction and diffuse changes (all four ventricles) typical of cathecholamine cardiomyopathy. The findings were considered compatible with TC with secondary myocardial rupture.</p><p><strong>Conclusion: </strong>An initial diagnosis of TC with myocardial rupture can be reasonably made by autopsy in the context of an appropriate clinical history and the presence of the characteristic microscopic features of cathecholamine excess in the myocardium.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"17 ","pages":"4"},"PeriodicalIF":0.0,"publicationDate":"2017-04-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0045-0","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34901433","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 21
Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma. 人表皮生长因子受体2在膀胱尿路上皮癌中的表达。
Q2 Medicine Pub Date : 2017-04-04 eCollection Date: 2017-01-01 DOI: 10.1186/s12907-017-0046-z
Mohamed Reda El Ochi, Mohamed Oukabli, Elarbi Bouaiti, Hafsa Chahdi, Adil Boudhas, Mohamed Allaoui, Ahmed Ameur, Mohamed Abbar, Abderrahmane Al Bouzidi

Background: Urothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters.

Methods: 103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody.

Results: HER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (p = 0.003) and pathological stage (p = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (P = 0.04).

Conclusion: HER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior.

背景:尿路上皮性膀胱癌(UBC)是世界范围内男性最常见的癌症之一。人表皮生长因子受体2 (HER2)在尿路上皮癌中广泛表达。尽管文献中有许多报道,但这种过表达的预后意义尚不清楚。本研究的目的是评估HER2在尿路上皮性膀胱癌中的表达及其与临床和病理参数的关系。方法:2014年1月至2015年12月在我科诊断的UBC患者103例。经尿道切除或膀胱切除术获得的肿瘤标本采用免疫组化HER2抗体进行评估。结果:11.7%的病例存在HER2蛋白过表达,并与肿瘤分级(p = 0.003)和病理分期(p = 0.015)相关。在多变量分析中,HER2过表达仅与肿瘤分级相关(P = 0.04)。结论:HER2蛋白在高级别肿瘤患者中存在过表达。这种表达可以选择抗HER2靶向治疗的患者。未来更大规模的前瞻性研究将验证HER2改变的频率以及HER2在攻击行为中的作用。
{"title":"Expression of human epidermal growth factor receptor 2 in bladder urothelial carcinoma.","authors":"Mohamed Reda El Ochi,&nbsp;Mohamed Oukabli,&nbsp;Elarbi Bouaiti,&nbsp;Hafsa Chahdi,&nbsp;Adil Boudhas,&nbsp;Mohamed Allaoui,&nbsp;Ahmed Ameur,&nbsp;Mohamed Abbar,&nbsp;Abderrahmane Al Bouzidi","doi":"10.1186/s12907-017-0046-z","DOIUrl":"https://doi.org/10.1186/s12907-017-0046-z","url":null,"abstract":"<p><strong>Background: </strong>Urothelial bladder carcinoma (UBC) is one of the most prevalent cancers in men worldwide. Human epidermal growth factor receptor 2 (HER2) expression has been detected in a wide range of urothelial carcinoma. Despite many reports in the literature, the prognostic significance of this overexpression remains unclear. The aim of this study was to assess the expression of HER2 in urothelial bladder carcinomas and its association with clinical and pathological parameters.</p><p><strong>Methods: </strong>103 cases of UBC were diagnosed in our department between January 2014 and December 2015. The tumor specimens obtained by transurethral resection or cystectomy were evaluated by immunohistochemistry using HER2 antibody.</p><p><strong>Results: </strong>HER2 protein overexpression was present in 11.7% of cases and associated with tumor grade (<i>p</i> = 0.003) and pathological stage (<i>p</i> = 0.015). In multivariate analysis, HER2 overexpression was associated only with tumor grade (<i>P</i> = 0.04).</p><p><strong>Conclusion: </strong>HER2 protein overexpression is noted in patients with high grade cancer. This expression may select patients for anti HER2 targeted therapy. Future larger and prospective studies will verify the frequency of HER2 alteration and the role of HER2 in the aggressive behavior.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"17 ","pages":"3"},"PeriodicalIF":0.0,"publicationDate":"2017-04-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0046-z","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"34901431","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Peritumoral lymphatic vessel density and invasion detected with immunohistochemical marker D240 is strongly associated with distant metastasis in breast carcinoma 免疫组织化学标记物D240检测的肿瘤周围淋巴管密度和浸润与乳腺癌的远处转移密切相关
Q2 Medicine Pub Date : 2017-02-10 DOI: 10.1186/s12907-017-0041-4
N. F. Norhisham, Choi Yen Chong, S. Safuan
{"title":"Peritumoral lymphatic vessel density and invasion detected with immunohistochemical marker D240 is strongly associated with distant metastasis in breast carcinoma","authors":"N. F. Norhisham, Choi Yen Chong, S. Safuan","doi":"10.1186/s12907-017-0041-4","DOIUrl":"https://doi.org/10.1186/s12907-017-0041-4","url":null,"abstract":"","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"17 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-10","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0041-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44656554","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 6
Mycetoma in a non-endemic area: a diagnostic challenge 非流行地区的Mycetoma:诊断挑战
Q2 Medicine Pub Date : 2017-02-02 DOI: 10.1186/s12907-017-0040-5
B. Efared, L. Tahiri, M. Boubacar, Gabrielle Atsam-Ebang, N. Hammas, E. Hinde, L. Chbani
{"title":"Mycetoma in a non-endemic area: a diagnostic challenge","authors":"B. Efared, L. Tahiri, M. Boubacar, Gabrielle Atsam-Ebang, N. Hammas, E. Hinde, L. Chbani","doi":"10.1186/s12907-017-0040-5","DOIUrl":"https://doi.org/10.1186/s12907-017-0040-5","url":null,"abstract":"","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":" ","pages":""},"PeriodicalIF":0.0,"publicationDate":"2017-02-02","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-017-0040-5","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45758322","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 14
Nucleic acid extraction from formalin-fixed paraffin-embedded cancer cell line samples: a trade off between quantity and quality? 从福尔马林固定石蜡包埋癌细胞系样品中提取核酸:数量与质量之间的权衡?
Q2 Medicine Pub Date : 2016-11-14 eCollection Date: 2016-01-01 DOI: 10.1186/s12907-016-0039-3
Caroline Seiler, Alan Sharpe, J Carl Barrett, Elizabeth A Harrington, Emma V Jones, Gayle B Marshall

Background: Advanced genomic techniques such as Next-Generation-Sequencing (NGS) and gene expression profiling, including NanoString, are vital for the development of personalised medicines, as they enable molecular disease classification. This has become increasingly important in the treatment of cancer, aiding patient selection. However, it requires efficient nucleic acid extraction often from formalin-fixed paraffin-embedded tissue (FFPE).

Methods: Here we provide a comparison of several commercially available manual and automated methods for DNA and/or RNA extraction from FFPE cancer cell line samples from Qiagen, life Technologies and Promega. Differing extraction geometric mean yields were evaluated across each of the kits tested, assessing dual DNA/RNA extraction vs. specialised single extraction, manual silica column based extraction techniques vs. automated magnetic bead based methods along with a comparison of subsequent nucleic acid purity methods, providing a full evaluation of nucleic acids isolated.

Results: Out of the four RNA extraction kits evaluated the RNeasy FFPE kit, from Qiagen, gave superior geometric mean yields, whilst the Maxwell 16 automated method, from Promega, yielded the highest quality RNA by quantitative real time RT-PCR. Of the DNA extraction kits evaluated the PicoPure DNA kit, from Life Technologies, isolated 2-14× more DNA. A miniaturised qPCR assay was developed for DNA quantification and quality assessment.

Conclusions: Careful consideration of an extraction kit is necessary dependent on quality or quantity of material required. Here we provide a flow diagram on the factors to consider when choosing an extraction kit as well as how to accurately quantify and QC the extracted material.

背景:先进的基因组技术,如下一代测序(NGS)和基因表达谱,包括NanoString,对于个体化药物的发展至关重要,因为它们使分子疾病分类成为可能。这在癌症治疗中变得越来越重要,有助于患者的选择。然而,它通常需要从福尔马林固定石蜡包埋组织(FFPE)中高效提取核酸。方法:在这里,我们比较了几种市售的人工和自动方法,用于从Qiagen, life Technologies和Promega的FFPE癌细胞系样品中提取DNA和/或RNA。在每个测试的试剂盒中评估不同的提取几何平均产量,评估双重DNA/RNA提取与专门的单次提取,基于手工硅柱的提取技术与基于自动磁珠的方法,以及随后的核酸纯度方法的比较,提供对分离的核酸的全面评估。结果:在评估的四种RNA提取试剂盒中,Qiagen公司的RNeasy FFPE试剂盒具有优越的几何平均产率,而Promega公司的Maxwell 16自动化方法通过定量实时RT-PCR获得了最高质量的RNA。在评估的DNA提取试剂盒中,来自Life Technologies的PicoPure DNA试剂盒分离出了2-14倍的DNA。开发了用于DNA定量和质量评估的小型qPCR检测方法。结论:根据所需材料的质量或数量,仔细考虑提取试剂盒是必要的。在这里,我们提供了一个流程图,说明在选择提取试剂盒时要考虑的因素,以及如何准确地定量和质量控制提取的物质。
{"title":"Nucleic acid extraction from formalin-fixed paraffin-embedded cancer cell line samples: a trade off between quantity and quality?","authors":"Caroline Seiler,&nbsp;Alan Sharpe,&nbsp;J Carl Barrett,&nbsp;Elizabeth A Harrington,&nbsp;Emma V Jones,&nbsp;Gayle B Marshall","doi":"10.1186/s12907-016-0039-3","DOIUrl":"https://doi.org/10.1186/s12907-016-0039-3","url":null,"abstract":"<p><strong>Background: </strong>Advanced genomic techniques such as Next-Generation-Sequencing (NGS) and gene expression profiling, including NanoString, are vital for the development of personalised medicines, as they enable molecular disease classification. This has become increasingly important in the treatment of cancer, aiding patient selection. However, it requires efficient nucleic acid extraction often from formalin-fixed paraffin-embedded tissue (FFPE).</p><p><strong>Methods: </strong>Here we provide a comparison of several commercially available manual and automated methods for DNA and/or RNA extraction from FFPE cancer cell line samples from Qiagen, life Technologies and Promega. Differing extraction geometric mean yields were evaluated across each of the kits tested, assessing dual DNA/RNA extraction vs. specialised single extraction, manual silica column based extraction techniques vs. automated magnetic bead based methods along with a comparison of subsequent nucleic acid purity methods, providing a full evaluation of nucleic acids isolated.</p><p><strong>Results: </strong>Out of the four RNA extraction kits evaluated the RNeasy FFPE kit, from Qiagen, gave superior geometric mean yields, whilst the Maxwell 16 automated method, from Promega, yielded the highest quality RNA by quantitative real time RT-PCR. Of the DNA extraction kits evaluated the PicoPure DNA kit, from Life Technologies, isolated 2-14× more DNA. A miniaturised qPCR assay was developed for DNA quantification and quality assessment.</p><p><strong>Conclusions: </strong>Careful consideration of an extraction kit is necessary dependent on quality or quantity of material required. Here we provide a flow diagram on the factors to consider when choosing an extraction kit as well as how to accurately quantify and QC the extracted material.</p>","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"16 ","pages":"17"},"PeriodicalIF":0.0,"publicationDate":"2016-11-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-016-0039-3","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"35118521","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 30
Chromosomal abnormality of acute promyelocytic leukemia other than PML-RARA: a case report of acute promyelocytic leukemia with del(5q) 急性早幼粒细胞白血病非PML-RARA染色体异常伴del(5q) 1例
Q2 Medicine Pub Date : 2016-10-04 DOI: 10.1186/s12907-016-0038-4
O. Imataki, M. Uemura
{"title":"Chromosomal abnormality of acute promyelocytic leukemia other than PML-RARA: a case report of acute promyelocytic leukemia with del(5q)","authors":"O. Imataki, M. Uemura","doi":"10.1186/s12907-016-0038-4","DOIUrl":"https://doi.org/10.1186/s12907-016-0038-4","url":null,"abstract":"","PeriodicalId":35804,"journal":{"name":"BMC Clinical Pathology","volume":"16 1","pages":""},"PeriodicalIF":0.0,"publicationDate":"2016-10-04","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1186/s12907-016-0038-4","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"66186842","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
期刊
BMC Clinical Pathology
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1